Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Octapharma clinical trials
The registry lists 71 studies whose lead sponsor is Octapharma. 8 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 15, 2026.
Keep track of what changes. Save the Octapharma studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Octapharma.
- Octapharma71 studiesSame company
Something wrong?
Focus areas
Conditions Octapharma leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 71. Browse all 71 →
- Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema AttacksRecruitingNCT06361537Phase 3
- Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent InfectionsRecruitingNCT07220915Phase 3
- Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or DeliveryRecruitingNCT04918173Phase 3
- Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary BypassRecruitingNCT06096116Phase 3
- Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) PatientsRecruitingNCT04929236Phase 3
- Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A PatientsRecruitingNCT03695978
- Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for SurgeryRecruitingNCT05936580Phase 4
- Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis StudyRecruitingNCT05935358Phase 4
- Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Adult Patients With Severe Hemophilia ATerminatedNCT04046848Phase 1/2
- Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive ProcedureActive, not recruitingNCT06429787
- Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency DiseasesActive, not recruitingNCT04640142Phase 3
- Effectiveness and Tolerability of Eqwilate in Real-life ConditionsActive, not recruitingNCT04106908
- Study of OCTAPLEX in Patients With Acute Major Bleeding on DOAC Therapy With Factor Xa InhibitorTerminatedNCT04867837Phase 3
- Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)CompletedNCT04502030Phase 3
- Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease (VWD) Patients <6 Years of AgeCompletedNCT04953884Phase 3
- Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS)CompletedNCT04508530Phase 3
- Active-control Randomized Trial Comparing 4-factor Prothrombin Complex Concentrate With Frozen Plasma in Cardiac SurgeryCompletedNCT05523297Phase 3
- Safety and Efficacy of Fibryga in Congenital Fibrinogen DeficiencyTerminatedNCT03793426
- Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP)TerminatedNCT03866798Phase 4
- Immune Tolerance Induction in Haemophilia A Patients Using Wilate or NuwiqTerminatedNCT03344003
- Octagam 10% Therapy in COVID-19 Patients With Severe Disease ProgressionCompletedNCT04400058Phase 3
- Bleeding Incidence in VWD Patients Undergoing On-Demand TreatmentCompletedNCT04053699
- Study to Monitor Subcutaneous Human Immunoglobulin Administered at Modified Dosing Regimens in Patients With Primary Immunodeficiency DiseasesCompletedNCT03939533Phase 3
- Clinical Study to Investigate the Efficacy and Safety of Wilate During Prophylaxis in Previously Treated Patients With VWDCompletedNCT04052698Phase 3
- Observational, Retrospective Study to Evaluate Coagulation Changes and the Influence of Antithrombin III Treatment in Patients With Severe COVID-19 InfectionCompletedNCT04651400
- Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.CompletedNCT02740335Phase 3
- Study of Octaplex (Human Prothrombin Complex Concentrate) and Fresh Frozen Plasma in Patients Under Vitamin K Therapy Antagonist Needing Urgent Surgery or Invasive ProceduresCompletedNCT00618098Phase 3
- The Effect of Subcutaneous Immunoglobulin Gammanorm on the Distribution of IgG Subclasses and on Immunity of Patients With Secondary ImmunodeficiencyCompletedNCT03369301
- Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy)CompletedNCT02728752Phase 3
- Non-interventional Post-authorisation Study to Document the Immunogenicity, Safety, and Efficacy of NUWIQCompletedNCT02962765
- Study of Octanorm Subcutaneous IG in Patients With PIDCompletedNCT01888484Phase 3
- Use of Prothrombin Complex Concentrate in Patients Admitted in Emergency Care Units for Severe Bleeding While Receiving Oral AnticoagulantsCompletedNCT03320603Not applicable
- Non-Interventional Study on the Tolerability and Efficacy of IVIGCompletedNCT02303093
- Use of Fibryga, a Fibrinogen Concentrate in Real World: Retrospective Collection of Clinical DataCompletedNCT04106895
- Study Evaluating Efficacy and Safety of Octanorm in Patients With DermatomyositisTerminatedNCT03686969Phase 3
- Observational Study of the Use of octaplasLG®.CompletedNCT03369314
- Trial Assessing Safety and Efficacy of Gammanorm® in Autoimmune DiseasesTerminatedNCT03656640
- Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) NeuropathyCompletedNCT02638207Phase 3
- Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Paediatric Patients With Severe Haemophilia ACompletedNCT03376516Phase 3
- Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophilia ACompletedNCT02256917Phase 3
- Study to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIIICompletedNCT01992549Phase 3
- Surveillance of Safety and Efficacy of Wilate in Patients With Von Willebrand DiseaseCompletedNCT01602419
- Human Cell Line-derived Recombinant Factor VIII (Human-cl-rhFVIII) in Previously Untreated PatientsCompletedNCT01712438Phase 3
- Clinical Study to Investigate the PK, Efficacy, and Safety of Wilate in Patients With Severe Hemophilia ACompletedNCT02954575Phase 3
- Efficacy and Safety Study of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After SurgeryCompletedNCT02267226Phase 3
- Study to Assess the Efficacy, Safety and Pharmacokinetic of Octafibrin in Paediatric Subjects With Fibrinogen DeficiencyCompletedNCT02408484Phase 3
- CLINICAL PHASE III STUDY TO MONITOR THE SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES, INCLUDING (BUT NOT LIMITED TO) THOSE WHO HAVE COMPLETED THE SCGAM-01 TRIALCompletedNCT03907241Phase 3
- Octaplas Pediatric Plasma Replacement TrialCompletedNCT02050841Phase 4
- Octaplas Pediatric Plasma Exchange TrialCompletedNCT01938378Phase 4
- Study to Investigate the Long-term Efficacy and Safety of Human-cl rhFVIII in Previously Treated Patients (PTPs)CompletedNCT01341912Phase 3